DaShenLin Pharmaceutical Group Résultats passés
Passé contrôle des critères 2/6
DaShenLin Pharmaceutical Group has been growing earnings at an average annual rate of 5.2%, while the Consumer Retailing industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 18.1% per year. DaShenLin Pharmaceutical Group's return on equity is 11.3%, and it has net margins of 3.2%.
Informations clés
5.2%
Taux de croissance des bénéfices
4.7%
Taux de croissance du BPA
| Consumer Retailing Croissance de l'industrie | 12.8% |
| Taux de croissance des recettes | 18.1% |
| Rendement des fonds propres | 11.3% |
| Marge nette | 3.2% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)
Sep 30
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Sep 03DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital
Aug 20Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%
Jun 17Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?
Jun 09Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?
May 21Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings
May 06Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Apr 09Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E
Mar 17Ventilation des recettes et des dépenses
Comment DaShenLin Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 26,539 | 850 | 7,520 | 93 |
| 30 Jun 24 | 25,885 | 907 | 7,310 | 86 |
| 31 Mar 24 | 25,336 | 1,068 | 7,077 | 79 |
| 31 Dec 23 | 24,531 | 1,166 | 6,824 | 81 |
| 30 Sep 23 | 24,154 | 1,287 | 6,719 | 75 |
| 30 Jun 23 | 23,519 | 1,239 | 6,611 | 80 |
| 31 Mar 23 | 22,518 | 1,148 | 6,433 | 80 |
| 31 Dec 22 | 21,248 | 1,036 | 6,293 | 74 |
| 30 Sep 22 | 19,222 | 896 | 5,923 | 71 |
| 30 Jun 22 | 18,425 | 860 | 5,702 | 56 |
| 31 Mar 22 | 17,377 | 835 | 5,430 | 51 |
| 31 Dec 21 | 16,759 | 791 | 5,198 | 45 |
| 30 Sep 21 | 16,446 | 1,013 | 4,913 | 13 |
| 30 Jun 21 | 15,697 | 1,113 | 4,651 | 10 |
| 31 Mar 21 | 15,280 | 1,122 | 4,411 | 6 |
| 31 Dec 20 | 14,583 | 1,062 | 4,178 | 5 |
| 30 Sep 20 | 13,593 | 1,014 | 3,881 | 0 |
| 30 Jun 20 | 12,829 | 917 | 3,694 | 1 |
| 31 Mar 20 | 11,925 | 799 | 3,562 | 1 |
| 31 Dec 19 | 11,141 | 703 | 3,424 | 0 |
| 30 Sep 19 | 10,601 | 674 | 3,292 | 2 |
| 30 Jun 19 | 10,029 | 624 | 3,169 | 1 |
| 31 Mar 19 | 9,404 | 569 | 3,053 | 1 |
| 31 Dec 18 | 8,859 | 532 | 2,906 | 1 |
| 30 Sep 18 | 8,421 | 522 | 2,710 | 0 |
| 30 Jun 18 | 8,003 | 515 | 2,542 | 0 |
| 31 Mar 18 | 7,718 | 505 | 2,393 | 0 |
| 31 Dec 17 | 7,421 | 475 | 2,275 | 0 |
| 30 Sep 17 | 6,992 | 462 | 2,152 | 0 |
| 30 Jun 17 | 6,824 | 458 | 2,052 | 0 |
| 31 Mar 17 | 6,545 | 433 | 1,960 | 0 |
| 31 Dec 16 | 6,274 | 430 | 1,867 | 0 |
| 30 Jun 16 | 5,681 | 427 | 1,665 | 0 |
| 31 Mar 16 | 5,464 | 415 | 1,584 | 0 |
| 31 Dec 15 | 5,265 | 395 | 1,541 | 0 |
| 31 Dec 14 | 4,545 | 266 | 1,341 | 0 |
| 31 Dec 13 | 3,707 | 197 | 1,071 | 0 |
Des revenus de qualité: 603233 has high quality earnings.
Augmentation de la marge bénéficiaire: 603233's current net profit margins (3.2%) are lower than last year (5.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 603233's earnings have grown by 5.2% per year over the past 5 years.
Accélération de la croissance: 603233's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 603233 had negative earnings growth (-33.9%) over the past year, making it difficult to compare to the Consumer Retailing industry average (6%).
Rendement des fonds propres
ROE élevé: 603233's Return on Equity (11.3%) is considered low.